001     157143
005     20240229133506.0
024 7 _ |a 10.1016/j.euf.2020.06.020
|2 doi
024 7 _ |a pmid:32660838
|2 pmid
024 7 _ |a altmetric:85602670
|2 altmetric
037 _ _ |a DKFZ-2020-01429
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Tschirdewahn, Stephan
|b 0
245 _ _ |a Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography-fusion Biopsy.
260 _ _ |a Amsterdam
|c 2021
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1642069663_472
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Nov;7(6):1300-1307
520 _ _ |a Multiparametric magnetic resonance imaging (mpMRI) and targeted biopsies (TBs) facilitate accurate detection of significant prostate cancer (sPC). However, it remains unclear how many cores should be applied per target.To assess sPC detection rates of two different target-dependent magnetic resonance imaging (MRI)/transrectal ultrasonography (TRUS)-fusion biopsy approaches (TB and target saturation [TS]) compared with extended systematic biopsies (SBs).Retrospective single-centre outcome of transperineal MRI/TRUS-fusion biopsies of 213 men was evaluated. All men underwent TB with a median of four cores per MRI lesion, followed by a median of 24 SBs, performed by experienced urologists. Cancer and sPC (International Society of Urological Pathology grade group ≥2) detection rates were analysed. TB was compared with SB and TS, with nine cores per target, calculated by the Ginsburg scheme and using individual cores of the lesion and its 'penumbra'.Cancer detection rates were calculated for TS, TB, and SB at both lesion and patient level. Combination of SB + TB served as a reference. Statistical differences in prostate cancer (PC) detection between groups were calculated using McNemar's tests with confidence intervals.TS detected 99% of 134 sPC lesions, which was significantly higher than the detection by TB (87%, p = 0.001) and SB (82%, p < 0.001). SB detected significantly more of the 72 low-risk PC lesions than TB (99% vs 68%, p < 0.001) and 10% (p = 0.15) more than that detected by TS. At a per-patient level, 99% of men harbouring sPC were detected by TS. This was significantly higher than that by TB and SB (89%, p = 0.03 and 81%, p = 0.001, respectively). Limitations include limited generalisability, as a transperineal biopsy route was used.TS detected significantly more cases of sPC than TB and extended SB. Given that both 99% of sPC lesions and men harbouring sPC were identified by TS, the results suggest that this approach allows to omit SB cores without compromising sPC detection.Target saturation of magnetic resonance imaging-suspicious prostate lesions provides excellent cancer detection and finds fewer low-risk tumours than the current gold standard combination of targeted and systematic biopsies.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Wiesenfarth, Manuel
|0 P:(DE-He78)1042737c83ba70ec508bdd99f0096864
|b 1
|u dkfz
700 1 _ |a Bonekamp, David
|0 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
|b 2
|u dkfz
700 1 _ |a Püllen, Lukas
|b 3
700 1 _ |a Reis, Henning
|b 4
700 1 _ |a Panic, Andrej
|b 5
700 1 _ |a Kesch, Claudia
|b 6
700 1 _ |a Darr, Christopher
|b 7
700 1 _ |a Heß, Jochen
|b 8
700 1 _ |a Giganti, Francesco
|b 9
700 1 _ |a Moore, Caroline M
|b 10
700 1 _ |a Guberina, Nika
|b 11
700 1 _ |a Forsting, Michael
|b 12
700 1 _ |a Wetter, Axel
|b 13
700 1 _ |a Hadaschik, Boris
|b 14
700 1 _ |a Radtke, Jan Philipp
|0 P:(DE-He78)79897f8897ff77676549d9895258a0f2
|b 15
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.euf.2020.06.020
|g p. S2405456920301863
|0 PERI:(DE-600)2861750-2
|n 6
|p 1300-1307
|t European urology focus
|v 7
|y 2021
|x 2405-4569
909 C O |p VDB
|o oai:inrepo02.dkfz.de:157143
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)1042737c83ba70ec508bdd99f0096864
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)79897f8897ff77676549d9895258a0f2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-01-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-18
920 2 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21